Richard R. Barakat

Richard R. Barakat's AcademicInfluence.com Rankings

Richard R. Barakat

Philosophy

#7227

World Rank

#10411

Historical Rank

Logic

#4289

World Rank

#5560

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Richard R. Barakat's Degrees

Bachelors Biology University of Pennsylvania

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Richard R. Barakat Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard R. Barakat's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. (2002) (1035)
Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. (2009) (835)
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. (2002) (629)
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. (2000) (545)
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. (2009) (529)
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. (2008) (527)
Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. (2012) (495)
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. (2002) (435)
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers (2005) (428)
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC) (2006) (373)
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? (2007) (357)
The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. (2006) (339)
The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. (2012) (330)
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. (2006) (315)
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma (2006) (303)
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. (2004) (294)
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. (1992) (286)
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). (2012) (254)
Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. (2014) (239)
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation (2002) (235)
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. (2003) (215)
Laparoscopic-assisted vaginal hysterectomy for endometrial cancer: clinical outcomes and hospital charges. (1999) (205)
Pathologic Ultrastaging Improves Micrometastasis Detection in Sentinel Lymph Nodes During Endometrial Cancer Staging (2013) (204)
Gynecologic cancer treatment and the impact of cancer-related infertility. (2005) (200)
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. (2003) (199)
Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? (2009) (199)
Stage IV ovarian cancer: impact of surgical debulking. (1997) (197)
Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy. (2003) (190)
Principles and Practice of Gynecologic Oncology (2009) (188)
Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease (2007) (187)
Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma (2006) (181)
The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology (2007) (178)
Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. (2006) (175)
Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. (2008) (174)
Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. (1994) (172)
The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. (2009) (168)
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. (2016) (168)
Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. (1994) (164)
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. (2010) (162)
The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. (2008) (162)
A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible? (2004) (157)
Prognostic Features of Surgical Stage I Uterine Carcinosarcoma (2007) (156)
The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. (2008) (154)
The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. (2005) (153)
Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. (2007) (152)
Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. (2006) (152)
Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma (2004) (151)
Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. (2005) (147)
Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. (2003) (145)
Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. (2006) (140)
Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. (2003) (139)
Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. (2011) (139)
Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. (2005) (138)
Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. (2007) (136)
Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. (2011) (136)
Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed? (2009) (132)
The role of surgical cytoreduction in Stage IV endometrial carcinoma. (1997) (131)
High incidence of positive peritoneal cytology in low-risk endometrial cancer treated by laparoscopically assisted vaginal hysterectomy. (2001) (130)
Cancer-Related Infertility in Survivorship (2009) (127)
Risk of endometrial carcinoma associated with BRCA mutation. (2001) (126)
The outcomes of patients with positive margins after excision for intraepithelial Paget's disease of the vulva. (2007) (123)
Pelvic exenteration for recurrent endometrial cancer. (1999) (122)
A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. (2010) (120)
A nomogram to predict postresection 5‐year overall survival for patients with uterine leiomyosarcoma (2012) (120)
Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. (2009) (119)
The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. (2008) (118)
Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. (2009) (118)
Endometrial Carcinomas in Women Aged 40 Years and Younger: Tumors Associated With Loss of DNA Mismatch Repair Proteins Comprise a Distinct Clinicopathologic Subset (2009) (112)
Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. (2005) (111)
Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? (2008) (110)
Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes (2000) (110)
Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? (2002) (110)
Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma (2010) (109)
Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. (2000) (107)
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. (2002) (106)
Management and follow-up of patients with adenocarcinoma in situ of the uterine cervix. (1995) (106)
A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. (2010) (104)
Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. (2008) (100)
Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes. (2009) (99)
Reproductive outcomes of patients undergoing radical trachelectomy for early-stage cervical cancer. (2011) (99)
Clinical Outcome of Isolated Serous Tubal Intraepithelial Carcinomas (STIC) (2013) (96)
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. (2011) (93)
Symptoms of Ovarian Cancer (2001) (93)
Complications associated with intraperitoneal chemotherapy catheters. (2001) (92)
Clinicopathologic Features of Rhabdomyosarcoma of Gynecologic Origin in Adults (2007) (92)
Laparotomy to Complete Staging of Presumed Early Ovarian Cancer (1996) (91)
Risk factors for recurrence of ovarian borderline tumors. (2011) (91)
A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. (2007) (90)
Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. (2006) (90)
Primary vaginal melanoma: A critical analysis of therapy (2006) (90)
Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. (2002) (89)
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. (2009) (89)
Ovarian disease in women with breast cancer (1994) (88)
Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. (2007) (88)
Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. (1997) (86)
Initial experience with Dargent's operation: the radical vaginal trachelectomy. (2008) (85)
Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. (2007) (84)
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. (1992) (84)
Palliative surgery for bowel obstruction in recurrent ovarian cancer:an updated series. (2003) (83)
Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. (2013) (82)
Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy. (2010) (82)
Expanding the Indications for Radical Trachelectomy: A Report on 29 Patients With Stage IB1 Tumors Measuring 2 to 4 Centimeters (2013) (81)
Improved survival for BRCA2‐associated serous ovarian cancer compared with both BRCA‐negative and BRCA1‐associated serous ovarian cancer (2012) (80)
Sentinel lymph node biopsy in the management of early-stage cervical carcinoma. (2011) (80)
Surgical resection of recurrent endometrial carcinoma. (2006) (79)
A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment. (1998) (78)
Clinicopathologic Analysis of Early-stage Sporadic Ovarian Carcinoma (2004) (78)
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. (2005) (78)
Is endometrial carcinoma intrinsically more aggressive in elderly patients? (2003) (78)
Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers. (2000) (77)
Subcutaneous Tumor Implantation After Laparoscopic Procedures in Women With Malignant Disease (2004) (77)
Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. (2004) (75)
A microRNA survival signature (MiSS) for advanced ovarian cancer. (2011) (75)
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. (2007) (75)
Sexual health needs and educational intervention preferences for women with cancer (2017) (75)
A cross-sectional study of the psychosexual impact of cancer-related infertility in women: third-party reproductive assistance (2010) (73)
Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. (1993) (72)
Comparing Surgical Outcomes in Obese Women Undergoing Laparotomy, Laparoscopy, or Laparotomy With Panniculectomy for the Staging of Uterine Malignancy (2007) (72)
Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. (2008) (71)
Long-Term Survival After Fertility-Sparing Surgery for Epithelial Ovarian Cancer (2009) (71)
Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. (1998) (70)
Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. (1995) (70)
Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. (2013) (69)
Splenectomy in recurrent epithelial ovarian cancer. (1999) (69)
Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. (2006) (69)
Salvage weekly paclitaxel in recurrent ovarian cancer. (1997) (68)
Pap Smears in Women with Endometrial Carcinoma (2001) (67)
Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. (2012) (67)
The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications. (2014) (67)
Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery (2015) (66)
The Revised 2009 FIGO Staging System for Endometrial Cancer: Should the 1988 FIGO Stages IA and IB Be Altered? (2010) (66)
Second‐Look Operation for Epithelial Ovarian Cancer: Laparoscopy or Laparotomy? (1996) (65)
Screening and the prevention of gynecologic cancer: endometrial cancer. (2006) (64)
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. (2007) (64)
Chemotherapy and total parenteral nutrition for advanced ovarian cancer with bowel obstruction. (1997) (64)
Epithelial ovarian cancer in the elderly: The memorial sloan‐kettering cancer center experience (2010) (64)
Hepatic resection for metastatic gynecologic carcinomas. (1997) (64)
Tertiary cytoreduction in patients with recurrent ovarian carcinoma. (2004) (63)
Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer. (2006) (63)
A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors. (2010) (63)
Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer. (2013) (62)
Pelvic exenteration with curative intent for recurrent uterine malignancies. (2012) (62)
The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. (2010) (62)
A prospective study of the feasibility and acceptability of a Web-based, electronic patient-reported outcome system in assessing patient recovery after major gynecologic cancer surgery. (2012) (60)
Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. (2007) (60)
Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer. (2002) (60)
A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. (2009) (60)
Cost-Effectiveness Analysis of Robotically Assisted Laparoscopy for Newly Diagnosed Uterine Cancers (2014) (59)
Transperitoneal laparoscopic pelvic and para-aortic lymph node dissection using the argon-beam coagulator and monopolar instruments: an 8-year study and description of technique. (2003) (58)
Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. (2012) (58)
Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. (2012) (57)
Observations on the role of circumflex iliac node resection and the etiology of lower extremity lymphedema following pelvic lymphadenectomy for gynecologic malignancy. (2007) (56)
Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study (2006) (56)
The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. (2011) (55)
Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer. (2013) (55)
Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. (2008) (54)
Breast cancer metastatic to abdomen and pelvis: role of surgical resection. (2003) (54)
Pelvic insufficiency fractures in patients with cervical and endometrial cancer treated with postoperative pelvic radiation. (2013) (54)
The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma (2005) (54)
Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. (2007) (53)
Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. (2012) (52)
Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma. (2011) (52)
Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. (2011) (52)
GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients. (2018) (52)
A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. (2009) (51)
Cervical Conization and Sentinel Lymph Node Mapping in the Treatment of Stage I Cervical Cancer: Is Less Enough? (2013) (51)
Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. (1995) (50)
The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. (2007) (50)
Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers. (2006) (50)
The role of laparoscopy in second-look evaluations for ovarian cancer. (2001) (50)
Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. (2001) (49)
Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. (2003) (49)
Contemporary quality of life issues affecting gynecologic cancer survivors. (2012) (48)
Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk. (2010) (48)
Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer. (2009) (48)
Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. (1998) (48)
The use of colorectal stents for palliation of large-bowel obstruction due to recurrent gynecologic cancer. (2004) (48)
A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery. (2009) (47)
Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. (1996) (47)
Association between initial diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with endometrial carcinoma (2000) (47)
Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival. (2005) (47)
Clinicopathologic features of early adenocarcinoma of the cervix initially managed with cervical conization. (2006) (46)
A prospective study of quality of life in patients undergoing pelvic exenteration: interim results. (2013) (46)
Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. (2004) (46)
Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger. (2011) (46)
Impact of age on survival of patients with ovarian cancer. (1993) (46)
Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer. (2010) (45)
Postoperative Pain Medication Requirements in Patients Undergoing Computer-Assisted (“Robotic”) and Standard Laparoscopic Procedures for Newly Diagnosed Endometrial Cancer (2013) (45)
Platinum‐based chemotherapy of high‐risk stage I epithelial ovarian cancer following comprehensive surgical staging (1993) (45)
The Zinc Finger Gene ZIC2 Has Features of an Oncogene and Its Overexpression Correlates Strongly with the Clinical Course of Epithelial Ovarian Cancer (2012) (45)
Development of Endometrial Cancer After Radiation Treatment for Cervical Carcinoma (2003) (45)
Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma. (2004) (44)
Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube. (1991) (44)
Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. (2010) (44)
Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. (2008) (44)
The effect of tamoxifen on the endometrium. (1995) (44)
Prognostic Significance of Supradiaphragmatic Lymphadenopathy Identified on Preoperative Computed Tomography Scan in Patients Undergoing Primary Cytoreduction for Advanced Epithelial Ovarian Cancer (2010) (43)
The value of MR imaging when the site of uterine cancer origin is uncertain. (2011) (43)
Borderline tumors of the ovary. (1994) (43)
Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapy. (2012) (42)
Metastatic breast carcinoma to the abdomen and pelvis. (1997) (42)
Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. (2012) (41)
Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. (2010) (41)
Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer. (2009) (40)
Fellowship learning curve associated with completing a robotic assisted total laparoscopic hysterectomy. (2014) (40)
Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer (2016) (39)
Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: a multi-institutional study. (2014) (39)
Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. (2008) (39)
The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions. (2004) (39)
Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma. (1998) (38)
Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. (2010) (38)
Continent urinary diversion and low-rectal anastomosis in patients undergoing exenterative procedures for recurrent gynecologic malignancies. (2000) (37)
Prognostic Value of Lymph Node Ratio and Clinicopathologic Parameters in Patients Diagnosed With Stage IIIC Endometrial Cancer (2012) (37)
Molecular profiling of endometrial cancers from African-American and Caucasian women. (2006) (37)
Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers. (1996) (37)
Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer. (2013) (37)
Craniotomy for central nervous system metastases in epithelial ovarian carcinoma. (2002) (36)
Lysophosphatidic acid acyltransferase‐β (LPAAT‐β) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival (2006) (36)
Tamoxifen and endometrial neoplasia. (1996) (36)
Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. (2010) (36)
Evaluation of germline PTEN mutations in endometrial cancer patients. (2005) (36)
Accuracy of frozen section diagnosis of ovarian borderline tumor. (2011) (35)
Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer (2005) (35)
Racial disparities in recurrence among patients with early‐stage endometrial cancer (2008) (34)
The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. (1993) (34)
Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer (2007) (33)
Comparison of uterine malignancies that develop during and following tamoxifen therapy. (2006) (33)
Contemporary issues in the management of endometrial cancer (1998) (33)
Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery (2007) (32)
Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. (2012) (32)
Molecular genetic characterization of tamoxifen-associated endometrial cancer. (2005) (32)
Ovarian carcinoma screening in women at intermediate risk (2005) (31)
Micrometastasis of endometrial cancer to sentinel lymph nodes: is it an artifact of uterine manipulation? (2010) (31)
Risk of Endometrial Carcinoma Associated With BRCA Mutation (2001) (31)
Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (2010) (31)
Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: an update on out of the box surgery. (2012) (31)
Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer. (2013) (31)
The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. (2003) (31)
Second-Look Laparotomy in Carcinoma of the Fallopian Tube (1993) (30)
Stratification of Intermediate-Risk Endometrial Cancer Patients into Groups at High Risk or Low Risk for Recurrence Based on Tumor Gene Expression Profiles (2005) (30)
Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system. (2008) (30)
What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma? (2008) (29)
Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. (2009) (29)
Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer. (1999) (29)
Ovarian and Uterine Disease in Women with Colorectal Cancer (1997) (29)
Peritoneal inclusion cysts: clinical characteristics and imaging features (2013) (29)
Intraperitoneal chemotherapy in the management of ovarian cancer (1993) (28)
Introduction of a computer-based surgical platform in the surgical care of patients with newly diagnosed uterine cancer: outcomes and impact on approach. (2012) (28)
Positive peritoneal cytology is highly predictive of prognosis and relapse patterns in stage III (FIGO 2009) endometrial cancer. (2013) (28)
Intraoperative hypothermia during primary surgical cytoreduction for advanced ovarian cancer: risk factors and associations with postoperative morbidity. (2013) (28)
0126: Squamous Cell Carcinoma Arising in Mature Cystic Teratoma of the Ovary: a Case Series and Review of the Literature (2006) (28)
Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. (2017) (27)
Incidence of Venous Thromboembolism After Minimally Invasive Surgery in Patients With Newly Diagnosed Endometrial Cancer (2012) (27)
Cystoscopic temporary ureteral catheterization during radical vaginal and abdominal trachelectomy. (2006) (26)
Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy. (2013) (25)
Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival. (2006) (25)
Laparoscopic Management of Adnexal Masses in Women With a History of Nongynecologic Malignancy (1995) (25)
Laparoscopic and hand-assisted laparoscopic splenectomy for recurrent and persistent ovarian cancer. (2006) (25)
Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass. (2009) (25)
Benign and hyperplastic endometrial changes associated with tamoxifen use. (1997) (24)
Distribution of radiolabeled monoclonal antibody MX35 F(ab')2 in tissue samples by storage phosphor screen image analysis: evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer. (1997) (24)
Surgical management of advanced or recurrent endometrial cancer. (2001) (24)
Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer. (2007) (24)
Brief report: Total pelvic exenteration‐A retrospective clinical needs assessment (2004) (24)
Tumoral Displacement into Fallopian Tubes in Patients Undergoing Robotically Assisted Hysterectomy for Newly Diagnosed Endometrial Cancer (2013) (22)
GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE). (2019) (22)
Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma. (2008) (22)
High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. (1997) (21)
Optimal (≤1 cm) but visible residual disease: is extensive debulking warranted? (2013) (21)
Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. (2008) (20)
External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. (2012) (20)
Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. (2009) (20)
Redefining Stage I Endometrial Cancer: Incorporating Histology, a Binary Grading System, Myometrial Invasion, and Lymph Node Assessment (2013) (20)
The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma (2002) (19)
GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function. (2020) (19)
Cost effectiveness and other assessments of adjuvant therapies for early breast cancer. (1995) (19)
Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery. (2012) (19)
Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations (2001) (19)
Follow-Up Study of the Correlation Between Postoperative Computed Tomographic Scan and Primary Surgeon Assessment in Patients With Advanced Ovarian, Tubal, or Peritoneal Carcinoma Reported to Have Undergone Primary Surgical Cytoreduction to Residual Disease of 1 cm or Smaller (2009) (18)
Colorectal Stents for Palliation of Large-Bowel Obstructions in Recurrent Gynecologic Cancer: An Updated Series (2008) (18)
Effects of Tamoxifen on Cervicovaginal Smears from Patients with Breast Cancer (2000) (18)
Advances in the management of endometrial carcinoma. (2011) (18)
Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. (2012) (18)
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer. (1999) (17)
Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancers. (2009) (17)
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer. (1994) (17)
Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. (2006) (17)
A Prospective Randomized Trial Comparing Patient-Controlled Epidural Analgesia to Patient-Controlled Intravenous Analgesia on Postoperative Pain Control and Recovery After Major Open Gynecologic Cancer Surgery (2009) (17)
Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer. (2012) (17)
Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: review of surgical technique, complications, and outcome. (2012) (16)
Surgical risk-reduction in carriers of BRCA mutations: where do we go from here? (2004) (15)
Tamoxifen and the endometrium. (1998) (15)
Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers. (2011) (15)
Location of Disease in Patients Who Die From Endometrial Cancer: A Study of 414 Patients From a Single Institution (2012) (15)
Pilot study prospectively evaluating the use of the measurement of preoperative sonographic endometrial thickness in postmenopausal patients with endometrial cancer (2005) (14)
Intrinsic resistance of cervical squamous cell carcinoma cell lines to methotrexate (MTX) as a result of decreased accumulation of intracellular MTX polyglutamates. (1993) (14)
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer. (1992) (14)
Laparoscopically assisted surgical staging for endometrial cancer (2005) (14)
Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation. (2004) (14)
Prognostic Significance of the Number of Postoperative Intraperitoneal Chemotherapy Cycles for Patients With Advanced Epithelial Ovarian Cancer (2014) (14)
Full-thickness diaphragmatic resection for stage IV ovarian carcinoma using the EndoGIA stapling device followed by diaphragmatic reconstruction using a Gore-tex graft: a case report and review of the literature. (2006) (14)
Diagnostic x-rays and risk of epithelial ovarian carcinoma in Jews. (2002) (14)
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary (2015) (13)
Role of laparoscopy in the evaluation of the adnexa in patients with stage IV breast cancer. (2004) (13)
Endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma with a background of complex atypical hyperplasia and final hysterectomy pathology. (2010) (13)
Sonohysterography compared with endometrial biopsy for evaluation of the endometrium in tamoxifen-treated women. (2004) (13)
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube and primary peritoneal cancer: A change in surgical approach (2004) (13)
Peritoneal Washings in Endometrial Carcinoma (2000) (12)
Handbook of Gynecologic Oncology (2002) (12)
Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene. (2000) (12)
Endometrial cancer metastatic to infrarenal aortic lymph nodes unrecognized during laparoscopic inframesenteric aortic lymph node dissection. (2004) (12)
Pretreatment of endometrial carcinoma cell lines with butyrate results in upregulation of Bax and correlates with potentiation of radiation induced cell kill. (2000) (11)
Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer. (2014) (11)
Adjuvant radiation for early stage endometrial cancer with lymphovascular invasion. (2008) (11)
Complex Atypical Hyperplasia of the Uterus: Characteristics and Prediction of Underlying Carcinoma Risk (2011) (11)
Multi-center prospective analysis of risk-reducing salpingo-oophorectomy to prevent BRCA-associated breast and ovarian cancer. (2006) (11)
Mesorectal lymph node involvement and prognostic implications at total pelvic exenteration for gynecologic malignancies. (2006) (11)
Laparoscopic findings during adnexal surgery in women with a history of nongynecologic malignancy. (2006) (11)
Resection of recurrent cervical cancer after total pelvic exenteration (2006) (10)
Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. (2013) (10)
Intraperitoneal administration of Taxol in the management of ovarian cancer. (1993) (10)
Four-year follow-up of outcomes following risk-reducing salpingo-oophorectomy in BRCA mutation carriers (2005) (10)
Raynaud's phenomenon in infertile women treated with bromocriptine. (1987) (10)
FrequentMutation of the PIK 3 CA Gene in Ovarian and Breast Cancers (2005) (10)
Fifth International Conference on Ovarian Cancer: challenges and opportunities. (2005) (9)
A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer. (2014) (9)
Laparoscopic bilateral salpingo-oophorectomy in breast cancer patients after transverse rectus abdominus myocutaneous flap reconstructive surgery. (2005) (9)
Is Robotic-Assisted Surgery Safe in the Elderly Population? An Analysis of Gynecologic Procedures in Patients ≥ 65 Years Old (2018) (9)
Sonohysterography Compared With Endometrial Biopsy for Evaluation of the Endometrium in Tamoxifen‐Treated Women (2003) (9)
Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer. (2012) (9)
Ligation of an anatomic variant of renal vasculature during laparoscopic periaortic lymph node dissection: a cause of postoperative renal infarction. (2003) (9)
The accuracy of frozen-section diagnosis in metastatic breast and colorectal carcinoma to the adnexa. (1999) (9)
Ureteroileocecal appendicostomy based urinary reservoir in irradiated and nonirradiated patients. (2009) (9)
Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease. (1997) (9)
Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy (2005) (8)
Aggressive surgery and ovarian cancer. (2006) (8)
What do we expect from imaging? (2002) (8)
Use of hormone suppression then oocyte freezing to preserve reproductive capability in an adolescent girl with ovarian luteinized thecoma associated with sclerosing peritonitis. (2009) (8)
Atlas of Procedures in Gynecologic Oncology (2003) (8)
IV.6 Tamoxifen and endometrial cancer: most cancers are early stage and highly curable (1998) (8)
Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma. (2006) (8)
Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look. (2000) (8)
Epithelial ovarian carcinoma and European birthplace of grandparents. (2001) (8)
The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy. (2006) (8)
Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery. (1993) (8)
Herniation formation in women undergoing robotically assisted laparoscopy or laparotomy for endometrial cancer. (2016) (7)
The Role of Laparoscopy in Second-Look Evaluations for Ovarian Cancer (2001) (7)
Pelvic cytoreduction with rectosigmoid resection. (2007) (7)
Diethyldithiocarbamate chemoprotection of carboplatin-induced hematological toxicity (2005) (7)
WNK1 haplotypes and bevacizumab-induced hypertension (2008) (7)
Radical Surgery With Individualized Postoperative Radiation for Stage IB Cervical Cancer: Oncologic Outcomes and Severe Complications (2013) (7)
Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for uterine or cervical cancers. (2010) (7)
Allergy to latex surgical gloves: an unfamiliar cause of intraoperative anaphylaxis. (1992) (7)
A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer. (1997) (6)
High Incidence of Positive Peritoneal Cytology in Low-Risk Endometrial Cancer Treated by Laparoscopically-Assisted Vaginal Hysterectomy (2001) (6)
Automated Primary Screening Devices (2000) (6)
Surgery for malignant gynecologic disease (1993) (6)
GOG 244, the lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients (2018) (6)
Sister Society Meeting on Global Education Development and Collaboration: Meeting Report. (2016) (6)
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment. (1993) (6)
Enhancement of Ovarian Malignancy on Clinical Contrast Enhanced MRI Studies (2013) (5)
Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer. (2017) (5)
Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate (2005) (5)
Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma. (1999) (5)
Sister Society Meeting on Global Education Development and Collaboration: Meeting Report (2016) (4)
Corrigendum to “Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy” [Gynecol. Oncol. 91 (2003) 402–409] (2004) (4)
Improved overall survival for patients with advanced ovarian, tubal, and primary peritoneal carcinoma as a result of a change in surgical approach: A follow-up study (2007) (4)
Primary intravenous paclitaxel and platinum chemotherapy for high-risk Stage I epithelial ovarian carcinoma. (1999) (4)
Intravaginal high dose rate brachytherapy for uterine-confined endometrial cancer (2000) (4)
Paclitaxel and carboplatin (TP) for treatment of advanced or recurrent endometrial cancer: A retrospective study (2005) (4)
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease? (1992) (4)
The feasibility of mediastinal lymphadenectomy in the management of advanced and recurrent ovarian carcinoma (2011) (4)
The Effects of Tamoxifen on the Endometrium (2004) (4)
Sentinel lymph node mapping for grade 1/2 endometrial cancer with superficial myoinvasion: Less is more (2011) (3)
0231: Response and Outcomes in Elderly Patients with Stage Iiic-Iv Ovarian Cancer Receiving Platinum- Taxane Chemotherapy (2006) (3)
Is there a difference in outcome between stage I-II endometrial cancer of papillary serous (PS)/clear cell (CC) histologies and endometrioid FIGO grade 3 (2001) (3)
Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower extremity lymphedema after sentinel lymph node mapping (SLNM) compared to lymphadenectomy (2018) (3)
Prevention of Gynecologic Malignancies (2004) (3)
Should Women Receiving Tamoxifen for Breast Cancer Be Screened for Endometrial Cancer? (2000) (3)
Sentinel lymph node mapping: A valuable tool for assessing nodal metastasis in low grade endometrial cancer with superficial myoinvasion (2013) (3)
Feasibility and yield of offering genetic counseling to all patients with newly diagnosed high-grade epithelial ovarian cancer. (2011) (3)
Molecular Pathogenesis of Endometrial Cancer (2000) (3)
Abstract P2-12-05: Limited Absorption of Low Dose 10µg Intravaginal 17-β Estradiol (Vagifem®) in Postmenopausal Women with Breast Cancer on Aromatase Inhibitors (2012) (3)
Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second‐look assessment (2008) (3)
5Risk of developing uterine corpus cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations (2014) (3)
Recurrent cervical cancer isolated to the sigmoid colon: A case report☆ (2013) (3)
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal, and peritoneal carcinoma (2007) (3)
Phase II trial of zeniplatin (CL 286 558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy (2005) (2)
Proceedings from the 9th International Conference on Ovarian Cancer. (2012) (2)
Sentinel lymph node mapping in patients with vulvar malignancies using indocyanine green and near-infrared imaging: Preliminary detection rate experience (2015) (2)
Sentinel lymph node mapping in patients with endometrial cancer undergoing robot-assisted or standard laparoscopic procedures (2011) (2)
Cyclic hormonal changes in patients with congenital abscence of the uterus. (1977) (2)
0123: Toxicities of Modified Outpatient Regimen of Iv/Ip Paclitaxel and Ip Cisplatin in Women with Newly Diagnosed Ovarian Cancer (2006) (2)
Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapy (2005) (2)
Memorial Sloan-Kettering Cancer Center Experience with Intraperitoneal Chemotherapy of Ovarian Cancer (2000) (2)
Nanometastases of Endometrial Carcinoma to Sentinel Lymph Nodes: The Contribution of Pathologic Ultrastaging (2012) (2)
Utility of ovarian cancer screening in women with BRCA mutations (2008) (2)
Endometrial Cancer Prevention (2019) (2)
Superior pubic rami resection for isolated recurrent uterine cancer. (2007) (2)
Feasibility of Adjuvant Chemotherapy After Pelvic Exenteration for Gynecologic Malignancies (2013) (2)
Laparoscopic staging procedures (2008) (2)
Does removal of a positive sentinel node without lymphadenectomy impact pelvic sidewall control in endometrial cancer (2014) (2)
Does operative start time impact the frequency of complete gross resection in patients undergoing primary cytoreduction for advanced serous ovarian carcinoma (2011) (1)
Molecular Pathogenesis of Endometrial Cancer: The Role of Tamoxifen (2000) (1)
Costs of incorporating computer-based surgical platforms in the management of patients with newly diagnosed uterine cancers (2013) (1)
Oncologic outcomes of radical trachelectomy at a single institution (2011) (1)
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma. (1993) (1)
Unraveling the cause of death in endometrial cancer: A study of 2513 patients from a single institution (2012) (1)
Cost-effectiveness analysis of robotically assisted radical hysterectomy for newly diagnosed uterine cervical cancer (2015) (1)
Expanding radical trachelectomy for cervical cancer with tumor ≥ 2 centimeters: A report of 29 cases (2012) (1)
Do patients with complete gross resection of advanced stage ovarian cancer benefit from lymphadenectomy (2012) (1)
Incidence of adnexal and lymph node metastases in endometrial stromal sarcoma. (2009) (1)
Comprar Principles and Practice of Gynecologic Oncology,6/e | Dr.Richard R. Barakat FACS | 9781451176599 | Lippincott Williams & Wilkins (2013) (1)
Redefining stage I endometrial cancer: Incorporating histology, grade, myoinvasion, and whether or not lymph nodes were removed (2013) (1)
Quantifying the Risk of Recurrence and Death in Stage III (FIGO 2009) Endometrial Cancer (2013) (1)
Centralization of endometrial cancer care: Implications of preoperative subspecialty gynecologic pathology review (2017) (1)
Revolving door of obstruction – An analysis of gynecologic oncology readmission (2013) (1)
Impact of risk-reducing oophorectomy on quality of life in women at risk for ovarian cancer (2007) (1)
The benefit of a special elective gynecologic oncology program for obstetrics and gynecology residents. (2001) (1)
A survey of female cancer patients’ awareness of and preferences for receiving sexual health interventions (2014) (1)
Vulvovaginal melanoma: An institutional experience (2013) (1)
Staging and surgical treatment. (2009) (1)
The Journal of Clinical Cytology and Cytopathology (2001) (1)
Learning curve associated with becoming proficient in completing a robotic-assisted total laparoscopic hysterectomy: A single-institution gynecologic oncology fellowship experience (2013) (1)
Surgical cytoreduction as part of the initial management of patients diagnosed with metastatic uterine leiomyosarcoma (2012) (1)
Nomogram for predicting 5-year survival after primary surgery for epithelial ovarian cancer. (2009) (1)
Cytoreductive surgery: intestinal tract and omentum (2005) (1)
Use of intravaginal 17-β estradiol to improve sexual function and menopausal symptoms in postmenopausal women with breast cancer on aromatase inhibitors. (2013) (1)
DNA mismatch repair protein defects and endometrial cancer in women age 40 and younger. (2009) (1)
Does postmenopausal risk-reducing salpingo-oophorectomy reduce the risk of BRCA-associated breast cancer? (2013) (1)
Clinical Approach to Diagnosis and Management of Endometrial Hyperplasia and Carcinoma. (2011) (1)
Incidence of sentinel lymph node metastasis in endometrial carcinoma: Correlation with tumor grade and myometrial invasion (2012) (1)
The prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced stage epithelial ovarian cancer. (2009) (0)
Fallopian T ube a nd P rimary P eritoneal C arcinomas A ssociated With BRCA Mutations (2003) (0)
Enrollment for cooperative group trials at a comprehensive cancer center (2013) (0)
Radical hysterectomy: programmatic change to reduce laparotomy rate while maintaining oncologic outcome for early stage cervical cancer (2015) (0)
Epithelial ovarian cancer in the elderly: The memorial sloankettering cancer center experience (1992) (0)
Does intraoperative hypothermia contribute to postoperative morbidity in patients undergoing optimal primary surgical cytoreduction for advanced ovarian cancer (2012) (0)
Patterns of Relapse in Stage I-II Uterine Papillary Serous Carcinoma Treated With Adjuvant Intravaginal Radiation (IVRT) (2013) (0)
The changing clinical features of cervical adenocarcinoma: Increasing proportion but favorable oncologic outcome (2012) (0)
Perspective: Should we remove a woman's ovaries to prevent ovarian Ca? (2002) (0)
Impact of bilateral oophorectomy on contralateral breast cancer risk in BRCA negative women from site-specific hereditary breast cancer kindreds. (2013) (0)
Comparison of robot-assisted and standard laparoscopic procedures in patients with endometrial cancer (2011) (0)
Survival benefit for BRCA-associated epithelial ovarian cancer (OC) is not explained by primary platinum sensitivity alone (2008) (0)
Incidence of ovarian cancer in BRCA-negative hereditary breast cancer families. (2004) (0)
What influence does hormone replacement therapy have on endometrial cancer risk? (2005) (0)
Feasibility and safety of same-day discharge after minimally invasive hysterectomy alone or with other procedures for benign and malignant indications (2012) (0)
923 Phase I study of taxol administered weekly in patients with persistent ovarian cancer (1995) (0)
Cancer risks in women from BRCA-negative hereditary breast and ovarian cancer families (2013) (0)
Outcome of early stage endometrial cancer in elderly patients (2002) (0)
Plastic reconstructive procedures (2018) (0)
Outcomes of surgery for stage IB cervical cancer: Variations between squamous and adenocarcinoma histology (2011) (0)
LAPAROSCOPICALLY ASSISTED SURGICAL STAGING FOR ENDOMETRIAL CANCER: 0016 (2005) (0)
Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for advanced ovarian cancer. (2010) (0)
A Comparison of Primary Intraperitoneal Chemotherapy to Consolidation Intraperitoneal Chemotherapy in Optimally Resected Advanced Ovarian Cancer (2014) (0)
A Comparison of Primary Intraperitoneal Chemotherapy to Consolidation Intraperitoneal Chemotherapy in Optimally Resected Advanced Ovarian Cancer (2014) (0)
Change in patient weight during platinum/paclitaxel-based chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. (2006) (0)
The use of recombinant human erythropoietin to prevent carboplatin‐induced anemia (1994) (0)
1055 : A Paradigm Shift in Treatment of Early-Stage Endometrial Cancer and its Effect on Outcome in Patients With Lymphovascular Invasion (2006) (0)
Outcomes for patients with advanced epithelial ovarian cancer treated with adjuvant chemotherapy at a regional network facility compared to the central campus (2015) (0)
Isolated Lymph Node Recurrence is Associated with Improved Survival in Advanced Stage Ovarian Cancer (2012) (0)
0012: Radical Trachelectomy for Endocervical Adenocarcinoma: Pitfalls of Frozen-Section Management (2006) (0)
John L. Lewis, Jr., MD 1929–2012 (2013) (0)
Oncologic outcomes of “cut through” radical trachelectomy for early-stage cervical cancer (2011) (0)
Iconographies supplémentaires de l'article : Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? (2011) (0)
Extent of lymphadenectomy in patients with node-positive (FIGO stage IIIC) endometrial carcinoma. (2011) (0)
Incidence of lymph node metastasis in comprehensively staged clear cell carcinoma grossly confined to the ovary (2014) (0)
Estrogen replacement therapy in patients with endometrial cancer: A survey of prescription intention of Belgian gynecologists (1999) (0)
Integration of and training for robot-assisted surgery in a gynecologic oncology fellowship program (2011) (0)
Postoperative pain medication requirements in patients undergoing robotically assisted and standard laparoscopic procedures for newly diagnosed endometrial cancer (2011) (0)
Impact of sentinel lymph node mapping algorithm on identification of stage IIIC endometrial cancer (2012) (0)
Comparison of Early-Stage Uterine Papillary Serous Carcinoma (UPSC) and Carcinosarcoma Treated With Adjuvant Carboplatin/Taxane Chemotherapy and Intravaginal Radiation Therapy (IVRT) (2014) (0)
The safety and efficacy of bevacizumab therapy in recurrent ovarian carcinoma (2008) (0)
Postoperative IMRT for Cervical and Endometrial Cancer (2011) (0)
Hereditary breast and ovarian cancer syndrome based on family history alone and implications for patients with serous carcinoma (2011) (0)
The significance of positive peritoneal cytology in stage III endometrial cancer (2013) (0)
Utilization of specialized postoperative services in a comprehensive surgical cytoreduction program (2011) (0)
Impact of lymph node ratio and clinico-pathologic parameters on stage IIIC endometrial cancer prognosis: A validation study (2012) (0)
Atlas of Procedures in Gynecologic Oncology: Memorial Sloan‐Kettering Cancer Center (2003) (0)
Management and outcome of recurrent epithelial ovarian cancer after negative second-look (1992) (0)
CASE REPORT Allergy to Latex Surgical Gloves: An Unfamiliar Cause of lntraoperative Anaphylaxis (1992) (0)
Patterns of recurrence and associated clinical factors in patients with advanced serous ovarian cancer who experience a CA125 negative recurrence (2012) (0)
Advances in the Treatment of Gynecologic Malignancies (2002) (0)
Combined preoperative and extended pharmacologic venous thromboembolic prophylaxis in patient undergoing surgery for advanced adnexal malignancies (2015) (0)
Maximizing minimally invasive surgical approaches in the morbidly obese patient with newly diagnosed uterine cancer (2014) (0)
Severe complications and oncologic outcome of stage IB cervical cancer treated with radical surgery and individualized post-operative radiation (2012) (0)
Multi gene panel testing in unselected patients (pts) with endometrial cancer (EC). (2017) (0)
Nodal selection during side-specific lymphadenectomy in cases of failed sentinel node mapping (2014) (0)
Impact of adjuvant chemotherapy in patients with FIGO stage I ovarian clear cell cancer in the platinum era: A Surveillance, Epidemiology, and End Results cohort study, 2000-2013 (2017) (0)
Criteria for Using Intraperitoneal (IP) Chemotherapy for Advanced Ovarian Cancer (2010) (0)
Baseline characteristics and concerns of cancer patients/survivors seeking treatment at a female sexual medicine program (2014) (0)
Lymph Node Involvement: Indicator or Instigator of Poor Outcome in Stage III Endometrial Cancer? (2012) (0)
Breast cancer risk with hormone replacement after risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Does it abrogate the benefit? (2014) (0)
Intraperitoneal carboplatin-etoposide salvage therapy in ovarian cancer (1992) (0)
0056: Surgical Removal of Pelvic Lymph Nodes Influences Endometrial Cancer Outcomes: an 11-Year Study (2006) (0)
Does minimally invasive surgery compromise the oncologic outcome of women with high-risk non-endometrioid endometrial carcinomas (2014) (0)
Strongly with the Clinical Course of Epithelial Ovarian Cancer Has Features of an Oncogene and Its Overexpression Correlates (2015) (0)
Is radical debulking the best strategy for treating ovarian cancer (2007) (0)
Association of personal and family history with decision to undergo risk-reducing salpingo-oophorectomy in BRCA mutation carriers (2005) (0)
Intravaginal brachytherapy (IVRT) alone for patients with endometrial cancer meeting the PORTEC inclusion criteria (2007) (0)
Outcomes in node-positive low-grade endometrioid endometrial carcinoma (2014) (0)
CLINICAL APPROACH TO DIAGNOSIS AND MANAGEMENT OF ENDOMETRIAL AND CARCINOMA (2011) (0)
Quantifying the Risk of Relapse in Early Stage Endometrial Cancer (2005) (0)
With Thanks to the International Journal of Gynecological Cancer: Reviewers of 2011 (2011) (0)
Urologic outcomes following modified Indiana pouch during pelvic exenteration for gynecologic malignancies (2013) (0)
0141: Management of Morcellated Gynecologic Malignancies Incidentally Found On Final Pathology (2006) (0)
Combined modality adjuvant therapy for FIGO stage IIIC endometrial carcinomas (2014) (0)
Herniation formation in women undergoing surgery for endometrial cancer (2016) (0)
Benefits of Tamoxifen Outweigh Endometrial Cancer Risk (1996) (0)
0735: Laparoscopic Staging of Previously Unstaged Endometrial Cancer (2006) (0)
Ki67 expression as a predictor for suboptimally debulked patients with advanced epithelial ovarian cancer (2007) (0)
Clinical outcome of Serous Tubal Intraepithelial Carcinomas (STIC) (2012) (0)
Impact of adjuvant chemotherapy in patients with FIGO stage I endometrioid ovarian carcinoma in the platinum era: A Surveillance, Epidemiology, and End Results cohort study, 2000-2013 (2017) (0)
GOG 244, The lymphedema and gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lower extremity lymphedema (2018) (0)
Comprar Atlas of Procedures in Gynecologic Oncology, Second Edition | Douglas A. Levine | 9781841844985 | Informa Healthcare (2008) (0)
Surgical ovarian ablation for hormone receptor positive primary breast cancer in premenopausal women. (2017) (0)
0079: Maximal Surgical Cytoreduction Increases Sensitivity to Platinum-Taxane Chemotherapy in Patients with Advanced Ovarian Cancer (2006) (0)
Primary fallopian tube lesions in BRCA mutation carriers undergoing risk-reducing surgery. (2010) (0)
Engaging human tumor microvascular endothelium to improve ionizing radiation outcomes in solid tumor treatment. (2006) (0)
Cytoreductive surgery for serous ovarian cancer in patients 75 years and older (2011) (0)
Utility of “reflex” CT scans during surveillance of serous ovarian cancer (2012) (0)
Correlation between preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma and final hysterectomy pathology (2008) (0)
Robotic radical hysterectomy: Extent of tumor resection and operative outcomes compared with laparoscopy and exploratory laparotomy (2011) (0)
Fallopian Tube Cancer (2006) (0)
Nomogram predicting 5-year progression-free survival after secondary surgical cytoreduction for platinum-sensitive recurrent ovarian cancer (2014) (0)
Risk Stratification of Death From Endometrial Cancer in Patients With Early Stage Disease (2007) (0)
Does para-aortic lymph node assessment during endometrial cancer staging impact overall survival? (2013) (0)
Clinical significance of defective mismatch repair in endometrial carcinoma (2005) (0)
Feasibility and perioperative outcomes of robotic-assisted surgery for the management of recurrence disease in gynecologic oncology: A multi-institutional study (2013) (0)
Is robotic-assisted surgery safe in the elderly population? An analysis of gynecologic procedures in patients ≥ 65 years old (2014) (0)
Immunohistochemical expression of ER and PR and outcomes in patients with newly diagnosed uterine leiomyosarcoma. (2010) (0)
Thanks to authors and peer reviewers (2007) (0)
PO-252 ADJUVANT CARBOPLATIN/PACLITAXEL AND INTRAVAGINAL RADIATION FOR STAGE I-II SEROUS ENDOMETRIAL CANCER (2012) (0)
Cost-effectiveness analysis of conventional laparoscopic versus robotically assisted laparoscopic adnexal surgery for benign indications performed by gynecologic oncologists (2015) (0)
Minimal access surgery compared with laparotomy for secondary cytoreduction in patients with recurrent ovarian carcinomas (2016) (0)
Effect of pelvic exenteration type and vaginal reconstruction on quality of life. (2010) (0)
Paper 5: The Safety and Efficacy of Laparoscopic Surgical Staging of Apparent Stage I Ovarian and Fallopian Tube Cancers (2004) (0)
Detection of sentinel lymph nodes using indocyanine green and near-in- frared fluorescence imaging for gynecological malignancies (2013) (0)
Early trends in CA 125 levels as predictors of response in a prospective trial of the treatment of advanced ovarian cancer (1992) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard R. Barakat?

Richard R. Barakat is affiliated with the following schools:

Institute of Cancer Research
Ohio State University
Icahn School of Medicine at Mount Sinai
University of Pennsylvania

Richard R. Barakat's Academic­Influence.com Rankings